JP2017501728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501728A5 JP2017501728A5 JP2016543004A JP2016543004A JP2017501728A5 JP 2017501728 A5 JP2017501728 A5 JP 2017501728A5 JP 2016543004 A JP2016543004 A JP 2016543004A JP 2016543004 A JP2016543004 A JP 2016543004A JP 2017501728 A5 JP2017501728 A5 JP 2017501728A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- amino acid
- binding fragment
- terminal amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920425P | 2013-12-23 | 2013-12-23 | |
| US61/920,425 | 2013-12-23 | ||
| PCT/CA2014/051263 WO2015095972A1 (en) | 2013-12-23 | 2014-12-23 | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017501728A JP2017501728A (ja) | 2017-01-19 |
| JP2017501728A5 true JP2017501728A5 (OSRAM) | 2018-02-01 |
| JP6585600B2 JP6585600B2 (ja) | 2019-10-02 |
Family
ID=53477259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543004A Active JP6585600B2 (ja) | 2013-12-23 | 2014-12-23 | Ｃ末端軽鎖ポリペプチド伸長を含有する抗体、ならびにその複合体及びその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11208497B2 (OSRAM) |
| EP (1) | EP3087185A4 (OSRAM) |
| JP (1) | JP6585600B2 (OSRAM) |
| KR (1) | KR20160122127A (OSRAM) |
| CN (1) | CN106459981A (OSRAM) |
| AU (1) | AU2014373593B2 (OSRAM) |
| BR (1) | BR112016014913A8 (OSRAM) |
| CA (1) | CA2934818C (OSRAM) |
| IL (1) | IL246371A0 (OSRAM) |
| MX (1) | MX2016008355A (OSRAM) |
| RU (1) | RU2016129724A (OSRAM) |
| SG (1) | SG11201605093VA (OSRAM) |
| WO (1) | WO2015095972A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6983511B2 (ja) | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
| CN120795163A (zh) * | 2016-10-14 | 2025-10-17 | 丹娜法伯癌症研究所公司 | 模块化四聚体双特异性抗体平台 |
| EP3579848B1 (en) | 2017-02-08 | 2024-10-30 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| EP3651807B1 (en) * | 2017-07-13 | 2023-11-01 | City of Hope | Phosphorothioate-conjugated peptides and methods of using the same |
| US11607457B2 (en) | 2017-07-13 | 2023-03-21 | City Of Hope | Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same |
| AU2018329937B2 (en) * | 2017-09-07 | 2024-09-12 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and nectin4 |
| BR112020015994A2 (pt) | 2018-02-08 | 2020-12-15 | Dragonfly Therapeutics, Inc. | Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer |
| MX2020008336A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d. |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| US12404512B2 (en) | 2018-05-01 | 2025-09-02 | Ambrx, Inc. | Method for optimizing antibody expression |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EA202190468A1 (ru) | 2018-08-08 | 2021-07-06 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| RS64205B1 (sr) | 2018-11-30 | 2023-06-30 | Bristol Myers Squibb Co | Antitelo koje sadrži c-terminalnu ekstenziju lakog lanca koja sadrži glutamin, njegovi konjugati, i postupci i primene |
| AR122018A1 (es) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | Proteínas que se unen a nkg2d, cd16 y clec12a |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| CN117164701A (zh) * | 2022-12-27 | 2023-12-05 | 优洛生物(上海)有限公司 | 一种经改造的抗体、其制备方法及其用途 |
| EP4548936A1 (en) | 2023-10-30 | 2025-05-07 | BioNTech SE | Antibody-drug conjugates having a tailor-made drug-to-antibody ratio |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2170589C2 (ru) | 1992-10-28 | 2001-07-20 | Генентек Инк. | Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты) |
| US6652863B1 (en) * | 1992-11-16 | 2003-11-25 | Centocor, Inc. | Method of reducing the immunogenicity of compounds |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US20050159343A1 (en) | 1999-03-26 | 2005-07-21 | Board Of Regents, University Of Texas System | Inhibitors of glycosaminoglycans |
| MXPA03002918A (es) | 2000-10-02 | 2004-04-20 | Arizeke Pharmaceuticals Inc | Composiciones y metodos para el transporte de agentes biologicamente activos a traves de barreras celulares. |
| WO2005000902A1 (en) | 2003-06-30 | 2005-01-06 | Mu-Hyeon Choe | The dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same |
| WO2007103288A2 (en) * | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| MX380352B (es) * | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| ES2528922T3 (es) * | 2007-07-16 | 2015-02-13 | Genentech, Inc. | Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso |
| EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
| US8865875B2 (en) * | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| EP2615115A3 (en) * | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
| CN115043946A (zh) | 2008-01-03 | 2022-09-13 | 斯克里普斯研究院 | 通过模块识别结构域的抗体靶向 |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| NZ603623A (en) * | 2008-10-10 | 2014-05-30 | Emergent Product Dev Seattle | Tcr complex immunotherapeutics |
| JP2012521360A (ja) * | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｋｖ１．３の選択的かつ強力なペプチド阻害剤 |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| BR122020001787A8 (pt) * | 2011-05-08 | 2023-04-25 | Legochem Biosciences Inc | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| AU2012274127B2 (en) * | 2011-06-22 | 2017-06-22 | F. Hoffmann-La Roche Ag | Removal of target cells by circulating virus-specific cytotoxic T-cells using MHC class I comprising complexes |
| EP2776061B1 (en) * | 2011-11-07 | 2019-08-14 | MedImmune, LLC | Multispecific and multivalent binding proteins and uses thereof |
| WO2013096829A2 (en) | 2011-12-22 | 2013-06-27 | Arizona Biomedical Research Commission | Activation of cellular assault processes in the treatment of glioblastoma multiforme |
| AU2013224851B2 (en) * | 2012-03-02 | 2018-03-01 | Ablynx Nv | Pseudomonas aeruginosa PcrV binding single variable domain antibodies |
| US20140186350A1 (en) | 2012-12-18 | 2014-07-03 | Novartis Ag | Compositions and methods for long acting molecules |
-
2014
- 2014-12-23 US US15/107,884 patent/US11208497B2/en active Active
- 2014-12-23 KR KR1020167019769A patent/KR20160122127A/ko not_active Withdrawn
- 2014-12-23 MX MX2016008355A patent/MX2016008355A/es unknown
- 2014-12-23 CA CA2934818A patent/CA2934818C/en active Active
- 2014-12-23 WO PCT/CA2014/051263 patent/WO2015095972A1/en not_active Ceased
- 2014-12-23 AU AU2014373593A patent/AU2014373593B2/en active Active
- 2014-12-23 EP EP14874786.8A patent/EP3087185A4/en not_active Withdrawn
- 2014-12-23 JP JP2016543004A patent/JP6585600B2/ja active Active
- 2014-12-23 RU RU2016129724A patent/RU2016129724A/ru unknown
- 2014-12-23 CN CN201480075958.5A patent/CN106459981A/zh active Pending
- 2014-12-23 SG SG11201605093VA patent/SG11201605093VA/en unknown
- 2014-12-23 BR BR112016014913A patent/BR112016014913A8/pt not_active Application Discontinuation
-
2016
- 2016-06-21 IL IL246371A patent/IL246371A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501728A5 (OSRAM) | ||
| JP2019520797A5 (OSRAM) | ||
| JP2019521643A5 (OSRAM) | ||
| RU2016129724A (ru) | Антитела, содержащие с-концевые удлинения полипептида легкой цепи, их конъюгаты и способы применения | |
| JP2019514361A5 (OSRAM) | ||
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| JP2017529067A5 (OSRAM) | ||
| JP2019504617A5 (OSRAM) | ||
| JP2020063262A5 (OSRAM) | ||
| JP2012523848A5 (OSRAM) | ||
| JP2017504578A5 (OSRAM) | ||
| MX2009012319A (es) | Polipeptidos que se unen a receptores fc con funciones efectoras modificadas. | |
| JP2015519055A5 (OSRAM) | ||
| NZ750366A (en) | Chimeric antigen receptors targeting bcma and methods of use thereof | |
| JP2017114866A5 (OSRAM) | ||
| BR112022001902A2 (pt) | Proteína biespecífica de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica e método para a produção da proteína biespecífica de ligação ao antígeno | |
| EA201500204A1 (ru) | Антитела к ox40 и способы их применения | |
| JP2018526970A5 (OSRAM) | ||
| RU2018142544A (ru) | Биспецифические связывающие белки и пути их применения | |
| JP2018527919A5 (OSRAM) | ||
| RU2016106577A (ru) | САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII | |
| JP2016536322A5 (OSRAM) | ||
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| JP2016527314A5 (OSRAM) | ||
| JP2016533174A5 (OSRAM) |